BAY 1214784 Completes Ph. I for Uterine Fibroids With Good Tolerability
BAY 1214784
oral hGnRH-R hormone receptor antagonist to treat of uterine fibroids, Ph. I completed from cell-based 2.5M cmpd HTS + opt. J. Med. Chem., Oct. 22, 2020 issue Bayer AG, Berlin, DE
Other molecules you may be interested in
ZN-c3
The Zentalis Wee1 inhibitor, ZN-c3 , is a highly selective kinase inhibitor that is currently being evaluated in Ph. II clinical trials in adult women with recurrent or persistent uterine serous carcinoma (USC). The starting pyrazolopyrimidinone series was from the WO2013126656 patent, and while the molecule is similar to other kinase [...]
YourChoice/UMN RAR-α antagonist
YCT529 ( YourChoice ) is a potential non-hormonal male contraceptive with impressive preclinical oral efficacy that is expected to enter clinical development in the first half of 2023. This retinoic acid receptor alpha (RAR-α) antagonist, discovered by Gunda Georg ’s lab at the University of Minnesota, was first disclosed in 2022 and [...]
BAY 1214784
October’s molecule, the Bayer hGnRH-R antagonist BAY 1214784 , is intended as an oral, once-daily treatment for uterine fibroids, a highly common problem in adult women that can lead to infertility. Existing treatments include hGnRH-R blockers which have undesirable side effects such as induction of menopausal symptoms due to their influence [...]
TDI-11861
sAC as a target for male contraception. Soluble adenylyl cyclase (sAC) is one of several ACs that catalyze the cyclization of ATP to form cyclic adenosine monophosphate (cAMP). cAMP is the second messenger in several signaling pathways including that which activates sperm to be capable of fertilizing eggs (“ capacitation ”). The target is [...]
